SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Angiology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Trübestein, G.
Right arrow Articles by Rudofsky, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trübestein, G.
Right arrow Articles by Rudofsky, G.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Naftidrofuryl in Chronic Arterial Disease. Results of a Controlled Multicenter Study

G. Trübestein

From the Medizinische Universitäts-Poliklinik Bonn, Federal Republic of Germany

H. Böhme

From the Zentralkrankenhaus Gauting, Federal Republic of Germany

H. Heidrich

From the Franziskus-Krankenhaus Berlin, Federal Republic of Germany

F. Heinrich

Krankenhaus Bruchsal, Federal Republic of Germany

H. Hirche

Institut fur Medizinische Informatik der Universität Essen, Federal Republic of Germany

U. Maass

From the Medizinische Hochschule Hannover, Federal Republic of Germany

H. Mörl

From the Medizinische Universitätsklinik Heidelberg, Federal Republic of Germany

G. Rudofsky

In a double blind, randomized multicenter study naftidrofuryl, a vasoactive substance, was compared with placebo in the treatment of 104 patients with chronic arterial occlusive disease. After a run-in period of four weeks the pa tients received either naftidrofuryl (600mg daily) or placebo over 12 weeks. The pain-free and the total walking distances improved significantly in both groups. However, the difference in the improvement of the pain-free walking distance was significant (p < 0.02) in favour of naftidrofuryl. There also was a difference in the improvement of the total walking distance in favour of naftidrofuryl which was not significant.

The results indicate that naftidrofuryl has a beneficial effect on the symp toms and lengthens the painfree walking distance in patients with arterial occlu sive disease.

Angiology, Vol. 35, No. 11, 701-708 (1984)
DOI: 10.1177/000331978403501103
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement